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What is already known {#bph14849-sec-0006}
=====================

Obesity promotes development of chronic kidney disease with or without other aetiological factors.Activation of CB~1~ receptors and/or iNOS induces renal oxidative stress, inflammation, fibrosis, and kidney dysfunction.

What this study adds {#bph14849-sec-0007}
====================

A novel, peripherally restricted, orally bioavailable, dual CB~1~ receptor/iNOS antagonist ameliorated obesity‐induced chronic kidney disease.Adiponectin signalling was also involved in the therapeutic effects of the dual CB~1~ receptor/iNOS antagonist.

What is the clinical significance {#bph14849-sec-0008}
=================================

Our results support clinical evaluation of peripherally restricted CB~1~ receptor antagonists in treating obesity and its co‐morbidities.Simultaneous action on two targets, CB~1~ receptors and iNOS, has clear therapeutic benefits.
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:   4‐hydroxynonenal
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:   kidney injury marker 1

LKB1

:   liver kinase B1
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:   renal proximal tubule cells

TIMP‐1

:   tissue inhibitor of metalloproteinase 1
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:   vehicle

1. INTRODUCTION {#bph14849-sec-0009}
===============

The prevalence of global obesity has risen significantly over the past three decades (Ng et al., [2014](#bph14849-bib-0044){ref-type="ref"}). Among its various complications, obesity has been shown to directly affect kidney function with or without other aetiological factors (Mathew, Okada, & Sharma, [2011](#bph14849-bib-0042){ref-type="ref"}). In fact, obesity is considered a risk factor not only for developing chronic kidney disease (CKD) but also for accelerating the progression of an existing kidney disease to a greater extent in obese, compared with non‐obese, subjects (Othman, Kawar, & El Nahas, [2009](#bph14849-bib-0046){ref-type="ref"}). Additionally, a higher body mass index in individuals with end‐stage renal disease remains a strong independent risk factor for its development after adjusting for 42 possible confounding parameters such as age, smoking status, history of myocardial infarction, serum cholesterol level, hypertension, and diabetes (Hsu, McCulloch, Iribarren, Darbinian, & Go, [2006](#bph14849-bib-0024){ref-type="ref"}). Therefore, there is a crucial need to explore new potential therapeutic pathways to prevent and/or reverse the deleterious effects of obesity on the kidney.

At the molecular level, obesity‐induced CKD may involve two signalling pathways that have been shown to be overactivated in the kidney during obesity: the endocannabinoid (eCB)/<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56> receptor system (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}) and <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250> (iNOS; Lee et al., [2012](#bph14849-bib-0034){ref-type="ref"}). The former, best known for its role in regulating energy homeostasis and metabolism (Bermudez‐Silva, Cardinal, & Cota, [2012](#bph14849-bib-0007){ref-type="ref"}), involves the endogenous cannabinoids, their synthesizing and breakdown enzymes, and the cannabinoid receptors. eCBs, acting via CB~1~ receptors in the kidney (Larrinaga et al., [2010](#bph14849-bib-0032){ref-type="ref"}; Lecru et al., [2015](#bph14849-bib-0033){ref-type="ref"}), induce renal dysfunction and fibrosis, whereas genetically deleting CB~1~ receptors or globally inhibiting them induces anti‐inflammatory and anti‐fibrogenic effects (Lecru et al., [2015](#bph14849-bib-0033){ref-type="ref"}; Steinberg & Cannon, [2007](#bph14849-bib-0053){ref-type="ref"}; Tam et al., [2010](#bph14849-bib-0057){ref-type="ref"}; Tam et al., [2018](#bph14849-bib-0056){ref-type="ref"}). In a previous study, we reported that a specific deletion of CB~1~ receptors in the renal proximal tubule cells (RPTCs) markedly attenuated the obesity‐induced lipid accumulation in the kidney, as well as renal dysfunction, injury, inflammation, and fibrosis via regulating the <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2212>/<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540>/<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=255#1263> signalling pathway (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}). These deleterious effects in RPTCs, mediated via activating CB~1~ receptors, also modify the shape of the mitochondria, leading to reduced oxygen consumption, ATP production, and mitochondrial dysfunction (Drori et al., [2019](#bph14849-bib-0021){ref-type="ref"}). An additional signalling pathway that may promote renal dysfunction and fibrosis is the activation of iNOS, an enzyme catalysing the production of the free radical NO. A substantial up‐regulation of iNOS, commonly considered the main perpetrator of autotoxicity under oxidative stress such as obesity (Bogdan, [1998](#bph14849-bib-0008){ref-type="ref"}), has been shown to promote kidney fibrosis (Ozbek et al., [2009](#bph14849-bib-0047){ref-type="ref"}). However, iNOS inhibitors lack oral bioavailability (Lopez‐Sanchez et al., [2010](#bph14849-bib-0038){ref-type="ref"}), and currently, there is no effective antifibrotic therapy approved for clinical use.

A molecule that may link CB~1~ receptors and iNOS, regarding their deleterious effect on the kidney in obesity, is <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3726>, as activation or blockade of either CB~1~ receptors or iNOS in adipose tissue regulates adiponectin expression, synthesis, and subsequent release (Bensaid et al., [2003](#bph14849-bib-0006){ref-type="ref"}; Dallaire et al., [2008](#bph14849-bib-0019){ref-type="ref"}; Jeon et al., [2012](#bph14849-bib-0026){ref-type="ref"}), and may also affect the signalling pathways of adiponectin via its receptors in the liver (Kabir et al., [2015](#bph14849-bib-0028){ref-type="ref"}; Tam et al., [2014](#bph14849-bib-0055){ref-type="ref"}). In fact, adiponectin and its receptors, <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=649> and <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=650>, are expressed in RPTCs (Perri et al., [2013](#bph14849-bib-0048){ref-type="ref"}), and down‐regulating the adiponectin signalling pathway, specifically in these cells, may induce obesity‐induced kidney injury. Interestingly, although adiponectin knockout mice have normal glucose tolerance, body weight, and blood pressure (Ma et al., [2002](#bph14849-bib-0039){ref-type="ref"}), they develop microalbuminuria at double the normal range at an early age and display elevated oxidative stress (Ohashi et al., [2007](#bph14849-bib-0045){ref-type="ref"}).

Here, we examined the effect of blocking the CB~1~ receptor and iNOS signalling pathways in ameliorating obesity‐induced CKD by using a novel peripherally restricted, orally bioavailable dual CB~1~ receptor/iNOS antagonist, MRI‐1867 (Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}). The results indicate that the beneficial effects of this compound on the kidney is partly associated with modulating adiponectin signalling in RPTCs.

2. METHODS {#bph14849-sec-0010}
==========

2.1. Animals and experimental protocol {#bph14849-sec-0011}
--------------------------------------

All animal care and experimental protocols were approved by the Institutional Animal Care and Use Committee of the Hebrew University (AAALAC Accreditation \#1285; Ethical Approval Number MD‐17‐15070‐3). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, Altman & Group, [2010](#bph14849-bib-0030){ref-type="ref"}) and with the recommendations made by the *British Journal of Pharmacology*. The current experiment is based on the rule of the replacement, refinement, or reduction. All the animals used in this study were housed under specific pathogen‐free conditions, up to five per cage, in standard plastic cages with natural soft sawdust as bedding. The animals were maintained under controlled temperature of 22--24°C, humidity at 55 ± 5%, and alternating 12‐hr light/dark cycles (lights were on between 7:00 a.m. and 7:00 p.m.) and provided with food and water *ad libitum*. To generate diet‐induced obesity (DIO; body weight \>50 g), 6‐week‐old male C57Bl/6J mice (The Jackson Laboratory, Cat\# 000664, RRID:IMSR_JAX:000664) were fed with either a high‐fat diet (HFD; 60% of calories from fat, 20% from protein, and 20% from carbohydrates; Research Diet, Cat\# D12492) or a standard diet (14% fat, 24% protein, and 62% carbohydrates; Cat\#, NIH‐31 rodent diet) for 18 weeks. Then, obese mice were randomly divided into the following experimental groups and treated orally for 28 consecutive days with either vehicle (Veh; 1% Tween 80, 4% DMSO, and 95% saline), the peripherally restricted dual CB~1~ receptor/iNOS antagonist, MRI‐1867 (3 mg·kg^−1^), a peripherally restricted CB~1~ receptor antagonist, JD5037 (3 mg·kg^−1^), or the iNOS inhibitor, <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=5102> (10 mg·kg^−1^). A parallel HFD group treated with Veh was pair fed to the MRI‐1867 group (Figure [S1](#bph14849-supitem-0001){ref-type="supplementary-material"}). The entire study included 58 animals in total (eight standard diet/Veh‐, 14 HFD/Veh‐, 14 HFD/MRI‐1867‐, eight HFD/JD5037‐, seven HFD/1400W‐treated mice and seven HFD/pair‐fed animals).

During the treatment, body weight and food intake were monitored every day. Mice were also subjected to a complete metabolic and renal analysis. Twenty‐four‐hour urine was collected 1 week before euthanasia using mouse metabolic cages (CCS2000 Chiller System, Hatteras Instruments, NC, USA). At week 22, mice were euthanized by a cervical dislocation under anaesthesia, the kidneys, brain, liver, fat pads, and muscles were removed and weighed, and samples were either snap frozen or fixed in buffered 4% formalin. Trunk blood was collected for determining the biochemical parameters.

2.2. Human kidney samples {#bph14849-sec-0012}
-------------------------

This study of human tissue samples was approved by the Rabin Medical Center Institutional Ethics Committee. Formalin‐fixed paraffin‐embedded renal biopsy materials were obtained from the pathological archives of the Department of Pathology at Rabin Medical Center, Israel. Kidney samples were obtained from unused portions of diagnostic kidney biopsies of patients with diabetic nephropathy (*n* = 8), obesity‐related glomerulopathy (ORG; *n* = 10), and focal segmental glomerulosclerosis (FSGS; *n* = 1). The control biopsies (normal; *n* = 6) were renal biopsies that appeared normal by histological, immunofluorescence, and electron microscopic examination. ORG was defined morphologically as FSGS and glomerulomegaly occurring in obese patients with a body mass index higher than 30 kg·m^−2^ (Wang et al., [2016](#bph14849-bib-0062){ref-type="ref"}).

2.3. Cell culture {#bph14849-sec-0013}
-----------------

Wild‐type or CB~1~ receptor deleted HK‐2 cells (see below) are human immortalized RPTCs (ATCC Cat\# CRL‐2190, RRID:CVCL_0302) and were cultured in REGM BulletKit medium (Lonza, USA) at 37°C in a humidified atmosphere of 5% CO~2~/95% air. Cell experiments under lipotoxic conditions were conducted at \>80% confluence in six‐well plates as described previously (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}). Briefly, lipotoxic conditions were established by incubating the cells with medium containing 1% fatty acid‐free BSA (Amresco, Cat\# 0332‐TAM), 0.5‐mM sodium oleate (Sigma‐Aldrich, Cat\# O7501), and sodium palmitate (Sigma‐Aldrich, Cat\# P9767) in a ratio of 2:1 and dissolved in 11% fatty acid‐free BSA (Sigma‐Aldrich, Cat\# A7030) and ultra‐pure DDW (Biological Industries, Cat\# 01‐866‐1A). MRI‐1867 (100 ng·ml^−1^ dissolved in DMSO), JD5037 (100 ng·ml^−1^ dissolved in DMSO), and 1400W (100 μg·ml^−1^ dissolved in saline) were added to the medium for 24 hr prior to collecting the cells for further evaluation. Cells were harvested using Bio‐Tri RNA lysis buffer (Bio‐Lab, Israel).

2.4. Genetic deletion of CB~1~ receptors in RPTCs {#bph14849-sec-0014}
-------------------------------------------------

HK‐2 cells were transfected with CRISPR‐CAS9 vector containing an sgRNA sequence to target all human isoforms of *CNR1* (Genecopeia™, Cat\# CS‐HCP263432‐CG01‐01‐B) using Lipofectamine 3000 (Invitrogen, Cat\# L3000‐001) and selected with hygromycin (200‐μM; Sigma‐Aldrich, Cat\# H3274). Antibiotic‐resistant cells were then seeded at single‐cell density and allowed to grow. Single‐cell clones were analysed by DNA sequencing and mRNA analysis to confirm the deletion of CB~1~ receptors as reported previously (Drori et al., [2019](#bph14849-bib-0021){ref-type="ref"}); these cells are referred to as CB~1~R^−/−^ HK‐2 cells.

2.5. ATP measurement {#bph14849-sec-0015}
--------------------

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> content in HK‐2 cells was quantified using an ATP assay kit (Abcam, Cat\# ab83355) following the manufacturer\'s instructions and as described previously (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}).

2.6. ROS measurement {#bph14849-sec-0016}
--------------------

ROS content in the medium of wild‐type or CB~1~R^−/−^HK‐2 cells was quantified using DCFDA---Cellular ROS Detection Assay Kit (Abcam, Cat\# ab113851) following the manufacturer\'s instructions.

2.7. Multi‐parameter metabolic assessment {#bph14849-sec-0017}
-----------------------------------------

Metabolic and activity profiles of the mice were assessed by using the Promethion High‐Definition Behavioral Phenotyping System (Sable Instruments, Inc., Las Vegas, NV, USA) as described previously (Knani et al., [2016](#bph14849-bib-0031){ref-type="ref"}; Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}).

2.8. Blood and urine biochemistry {#bph14849-sec-0018}
---------------------------------

Serum levels of creatinine and <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539> as well as urine levels of creatinine were determined by using the Cobas C‐111 chemistry analyzer (Roche, Switzerland). Blood urea nitrogen (BUN) was calculated by serum urea levels (BUN mg·dl^−1^ = Urea mM × 2.801). Creatinine clearance was calculated using urine and serum creatinine levels (CCr ml·hr^−1^ = Urine creatinine mg·dl^−1^ × Urine volume∕Serum creatinine mg·dl^−1^ × 24 hr). Urine levels of albumin, kidney injury marker 1 (KIM‐1), and <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5309>) were measured by [elisa]{.smallcaps} kits (albumin, Bethyl Laboratories, TX, USA; KIM‐1 and TIMP‐1, R&D Systems, MN, USA).

2.9. Histopathological analyses {#bph14849-sec-0019}
-------------------------------

Three‐micrometre paraffin‐embedded kidney sections from 7 to 14 animals per group were stained with periodic acid--Schiff, followed by haematoxylin staining. In addition, kidney sections were stained for collagen types I and III deposition by using Sirius Red (Abcam, Cat\# ab150681) and Masson\'s trichrome (Abcam, Cat\# ab150686) staining according to the manufacturer\'s procedures. Kidney images were captured with a Zeiss AxioCam ICc5 colour camera mounted on a Zeiss Axio Scope.A1 light microscope and taken from 10 random 40× fields of each animal. Mesangial expansion, glomerular, and Bowman\'s space cross‐sectional areas were quantified using ZEN imaging software (Zeiss, Germany). The Sirius Red‐ and Masson\'s trichrome‐positive areas were quantified in a blinded manner using ImageJ software with a minimum of 10 random kidney sections per mouse.

2.10. Immunohistochemistry {#bph14849-sec-0020}
--------------------------

The immuno‐related procedures used comply with the recommendations made by the *British Journal of Pharmacology,* (Alexander et al. [2018](#bph14849-bib-0003){ref-type="ref"} *)*. Kidney tissue was fixed in buffered 4% formalin for 48 hr and then embedded in paraffin. Sections were deparaffinized and hydrated. Heat‐mediated antigen was retrieved with 10‐mM citrate buffer pH 6.0 (Thermo Scientific, IL, USA). Endogenous peroxide was inhibited by incubating with a freshly prepared 3% H~2~O~2~ solution in MeOH. Non‐specific antigens were blocked by incubating sections for 1 hr with 2.5% horse serum (Vector Laboratories, Cat\# VE‐S‐2000). For assessment of tubulointerstitial fibrosis, 3‐μm mouse kidney sections were stained with rabbit anti‐mouse collagen‐1 (1:1,500; Abcam, Cat\# ab34710, RRID:AB_731684), <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771> (MCP‐1; 1:5,000; Abcam, Cat\# ab25124, RRID:AB_448636), iNOS (1:10,000; Abcam, Cat\# ab3523, RRID:AB_303872), TIMP‐1 (1:10,000; Proteintech, Cat\# 10753--1‐AP, RRID:AB_2204547), and <https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6274>; 1:2,000; Abcam, Cat\# ab46545, RRID:AB_722490) antibodies, followed by a goat anti‐rabbit IgG HRP conjugate (Vector Laboratories, Cat\# MP‐7401, RRID:AB_2336529). Human kidney biopsies were stained with rabbit anti‐human CB~1~ receptor (1:100; Alomone, Cat\# ACR‐001, RRID:AB_2039795) and iNOS (1:100; Abcam, Cat\# ab3523, RRID:AB_303872), followed by an HRP One‐Step Polymer Detection System: anti‐Mouse--Rabbit--Rat ZyoChem. Colour was developed after an incubation with 3,3′‐diaminobenzidine (DAB) substrate (Vector Laboratories, ImmPACT DAB Peroxidase (HRP) Substrate, Cat\# SK‐4105, RRID:AB_2336520), followed by haematoxylin counterstaining and mounting (Vector laboratories, Vecmount Cat\# H‐5000, RRID:AB_2336786). Stained sections were photographed as described above. The positive (stained) area for each marker was calculated using colour thresholding and by measuring area fractions with ImageJ software (NIH Public Domain, RRID:SCR_003070), with a minimum of 10 random kidney sections per mouse. Images are presented in the figures, showing the animal with the median value for each group.

2.11. Western blotting {#bph14849-sec-0021}
----------------------

The antibody‐based procedures used in this study comply with the recommendations made by the *British Journal of Pharmacology* (Alexander et al., [2018](#bph14849-bib-0003){ref-type="ref"}). Cells were harvested using Bio‐Tri RNA lysis buffer (Bio‐Lab, Israel), and proteins were extracted by isopropanol, 0.3‐M guanidine hydrochloride, and 0.1% SDS. Protein concentrations were measured with the Pierce™ BCA Protein Assay Kit (Thermo Scientific, IL, USA). Samples were resolved by SDS‐PAGE (4--15% acrylamide, 150V) and transferred to PVDF membranes using the Trans‐Blot^®^ Turbo™ Transfer System (Bio‐Rad, CA). Membranes were then incubated for 1 hr in 5% milk (in 1× TBS‐T) to block unspecific binding. Blots were incubated overnight with antibody against 4‐HNE (1:700; Abcam, Cat\# ab46545, RRID:AB_722490) and adiponectin (1:500; Abcam, Cat\# ab22554, RRID:AB_447152) at 4°C. Anti‐mouse (1:5,000) or rabbit (1:2,500) HRP‐conjugated secondary antibodies were used for 1 hr at room temperature, followed by chemiluminescence detection using the Clarity™ Western ECL Blotting Substrate (Bio‐Rad, CA). Densitometry was quantified using ImageJ (NIH Public Domain, RRID:SCR_003070). Quantification was normalized to anti‐β actin antibody (1:30,000; Abcam, Cat\# ab49900, RRID:AB_867494).

2.12. Real‐time PCR {#bph14849-sec-0022}
-------------------

Total mRNA from mouse kidney and HK‐2 cells was extracted using Bio‐Tri RNA lysis buffer (Bio‐Lab, Israel) followed by DNase I treatment (Thermo Scientific, IL, USA) and reverse transcribed using the iScript cDNA kit (Bio‐Rad, CA). Real‐time PCR was performed using iTaq Universal SYBR Green Supermix (Bio‐Rad, CA) and the CFX connect ST system (Bio‐Rad, CA). The following *Mus musculus* genes were detected: *Col1a1*, *Mcp1*, *Nos2*, *Timp‐1*, *Cnr1*, *Adipoq*, *Adipor1*, and *Adipor 2*. All genes were normalized to *Mus musculus* β‐actin (primer information is described in Tables [S1](#bph14849-supitem-0001){ref-type="supplementary-material"} and S2).

The expression of the following human genes was analysed: *ADIPOQ*, *ADIPOR1*, *ADIPOR2*, PDGF subunit A (*PDGFa*), *FGF2*, *MitoDNA*, and *β2M*. All genes were normalized to human *RPLP0* (primer information is described in Table [S1](#bph14849-supitem-0001){ref-type="supplementary-material"} and S2).

2.13. Total DNA extraction and mitochondrial DNA/genomic DNA measurement {#bph14849-sec-0023}
------------------------------------------------------------------------

Cells were harvested using trypsin, and DNA was extracted with the DNeasy Blood & Tissue Kit (Qiagen, Cat\# 69056) according to the manufacturer\'s protocol. Isolated DNA served as a template for qPCR reaction using primer sets for β~2~ microglobulin to amplify genomic DNA and D‐loop region to amplify mitochondrial DNA. Primer information is described in Tables [S1](#bph14849-supitem-0001){ref-type="supplementary-material"}.

2.14. Materials {#bph14849-sec-0024}
---------------

MRI‐1867 was kindly provided by Dr George Kunos of the NIH and synthesized as described previously (Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}). JD5037 was synthesized as described previously (Chorvat, Berbaum, Seriacki, & McElroy, [2012](#bph14849-bib-0013){ref-type="ref"}) and purchased from Haoyuan Chemexpress Co., Ltd. 1400W was purchased from Cayman Chemical.

2.15. Data and statistical analysis {#bph14849-sec-0025}
-----------------------------------

The data and statistical analysis comply with the recommendations of the *British Journal of Pharmacology* on experimental design and analysis in pharmacology. Randomization was used to assign samples to the experimental groups and treatment conditions for all in vivo studies. Data collection and acquisition of all in vivo and in vitro experimental paradigms were performed in a blinded manner. Data are expressed as the mean ± SEM. Statistical significance among groups and time‐dependent variables was compared by ANOVA, followed by a Bonferroni post hoc analysis using GraphPad Prism v6 for Windows (San Diego, CA; RRID:SCR_002798). Post hoc tests were conducted only if *F* was significant, and there was no variance inhomogeneity. Significance was set at *P* \< .05.

2.16. Nomenclature of targets and ligands {#bph14849-sec-0026}
-----------------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., [2018](#bph14849-bib-0023){ref-type="ref"}), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Christopoulos et al., [2017](#bph14849-bib-0001){ref-type="ref"}; Alexander, Fabbro et al., [2017](#bph14849-bib-0002){ref-type="ref"}).

3. RESULTS {#bph14849-sec-0027}
==========

3.1. Elevated expression of CB~1~ receptors and iNOS in CKD human patients {#bph14849-sec-0028}
--------------------------------------------------------------------------

To evaluate the contribution of CB~1~ receptors and iNOS to the development of CKD, we assessed their protein levels by immunohistochemistry in kidney biopsies from healthy humans (normal) and patients with FSGS, diabetic nephropathy, and ORG and found that both proteins were dramatically increased (Figure [1](#bph14849-fig-0001){ref-type="fig"}a). Interestingly, elevated protein levels were found in the tubular areas under all disease conditions. Whereas CB~1~ receptors were highly expressed in the proximal tubules, iNOS was mainly expressed in the distal tubules (Figure [1](#bph14849-fig-0001){ref-type="fig"}b,c).

![Elevated renal CB~1~ receptor (CB~1~R) and inducible NOS (iNOS) protein expression in humans with chronic kidney disease. (a) Elevated protein expression levels of CB~1~ receptors and iNOS were detected in 25 kidney biopsies from focal segmental glomerulosclerosis (FSGS), diabetic nephropathy (DN), and obesity‐related glomerulopathy (ORG) patients. (b, c) CB~1~ receptors and iNOS are highly expressed in the kidney tubules in DN and ORG. Scale bar, 100 μm in all images except for the right panels in (b), where the scale is 50 μm. Data represent the mean ± SEM from six normal, eight DN, and 10 ORG kidney samples. ^\*^ *P* \< .05, significantly different from normal kidney; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g001){#bph14849-fig-0001}

3.2. Dual blockade of CB~1~ receptors and iNOS induces a metabolic shift in diet‐induced obese mice {#bph14849-sec-0029}
---------------------------------------------------------------------------------------------------

To test the metabolic and renal effects of dual inhibition of CB~1~ receptors and iNOS in DIO mice, C57Bl/6J animals were maintained on an HFD for 18 weeks and then treated with MRI‐1867 (3 mg·kg^−1^, p.o.) or Veh for 28 days. A substantial body weight reduction (Figure [2](#bph14849-fig-0002){ref-type="fig"}a,b) and food intake inhibition (Figure [2](#bph14849-fig-0002){ref-type="fig"}c,d), with no effect on water intake (Figure [2](#bph14849-fig-0002){ref-type="fig"}e), were found in DIO animals treated with MRI‐1867. Additionally, these mice exhibited a decreased respiratory quotient (Figure [2](#bph14849-fig-0002){ref-type="fig"}f,g), an increased total energy expenditure (Figure [2](#bph14849-fig-0002){ref-type="fig"}h,i), and fat oxidation (Figure [2](#bph14849-fig-0002){ref-type="fig"}j,k), without a significant difference in carbohydrate oxidation (Figure [2](#bph14849-fig-0002){ref-type="fig"}l,m), suggesting higher fat utilization. The improved metabolic profile of DIO mice treated with MRI‐1867 was not associated with changes in ambulatory (Figure [S2a,b](#bph14849-supitem-0001){ref-type="supplementary-material"}) or voluntary (Figure [S2c,d](#bph14849-supitem-0001){ref-type="supplementary-material"}) activities as well as restoring the decreased ability of Veh‐treated DIO mice to run on a wheel (Figure [S2e,f](#bph14849-supitem-0001){ref-type="supplementary-material"}). Collectively, these metabolic effects are identical to those achieved by both central (Christopoulou & Kiortsis, [2011](#bph14849-bib-0014){ref-type="ref"}) and peripheral (Tam et al., [2012](#bph14849-bib-0054){ref-type="ref"}) CB~1~ receptor blockade, indicating that the contribution of iNOS inhibition to these metabolic effects is relatively small.

![MRI‐1867 improves the metabolic profile in diet‐induced obese mice. Male mice on standard diet (STD) or high‐fat diet (HFD) for 18 weeks were treated with vehicle (Veh) or MRI‐1867 (3 mg·kg^−1^) orally for 28 days. MRI‐1867 reduced (a, b) the body weight, (c) daily, and (d) the total food intake but not (e) the water intake. Metabolically, MRI‐1867 decreased (f, g) the respiratory quotient, which indicates a higher fat utilization, and increased (h, i) total energy expenditure (TEE) and (j, k) fat oxidation, without affecting (l, m) carbohydrate oxidation. Data represent the mean ± SEM from 8 to 14 mice per group. ^\*^ *P* \< .05, significantly different from animals on STD; ^\#^ *P* \< .05, significantly different from animals on the same diet; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g002){#bph14849-fig-0002}

3.3. Dual blockade of CB~1~ receptors and iNOS improves renal morphological and functional parameters in diet‐induced obese mice {#bph14849-sec-0030}
--------------------------------------------------------------------------------------------------------------------------------

Progressive morphological malformations and a decline in renal function, assessed by increased albuminuria, kidney injury markers, and changes in GFR, are common features associated with obesity‐related CKD in both humans and animals (Chagnac et al., [2008](#bph14849-bib-0009){ref-type="ref"}; Deji et al., [2009](#bph14849-bib-0020){ref-type="ref"}; Tobar et al., [2013](#bph14849-bib-0058){ref-type="ref"}; Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}). Indeed, Veh‐treated DIO mice displayed a glomerular enlargement (Figure [3](#bph14849-fig-0003){ref-type="fig"}a,b), increased Bowman\'s space area (Figure [3](#bph14849-fig-0003){ref-type="fig"}a,c), and mesangial expansion (Figure [3](#bph14849-fig-0003){ref-type="fig"}a,d). However, all of these changes were completely normalized by chronic MRI‐1867 treatment. Functionally, the significantly elevated urinary albumin (Figure [3](#bph14849-fig-0003){ref-type="fig"}e) and creatinine (Figure [3](#bph14849-fig-0003){ref-type="fig"}f) levels, also reflected by an up‐regulated albumin‐to‐creatinine ratio (Figure [3](#bph14849-fig-0003){ref-type="fig"}g) in DIO mice, were markedly attenuated by MRI‐1867. Similarly, chronic dual inhibition of CB~1~ receptors and iNOS was able to reverse the decrease in the kidney‐to‐body weight ratio (Figure [3](#bph14849-fig-0003){ref-type="fig"}h) and to ameliorate the elevation in the BUN levels (Figure [3](#bph14849-fig-0003){ref-type="fig"}i), as well as the urinary secretion levels of KIM‐1 (Figure [3](#bph14849-fig-0003){ref-type="fig"}j) and the TIMP‐1 (Figure [3](#bph14849-fig-0003){ref-type="fig"}k). Notably, treatment with MRI‐1867 insignificantly ameliorated the elevated creatinine clearance (CCr) noted in Veh‐treated DIO mice (Figure [3](#bph14849-fig-0003){ref-type="fig"}l).

![MRI‐1867 improves kidney morphology and function in diet‐induced obese mice. Mice on standard diet (STD) or high‐fat diet (HFD) for 18 weeks were treated with vehicle (Veh) or MRI‐1867 (3 mg·kg^−1^) orally for 28 days. Chronic MRI‐1867 treatment protected diet‐induced obese (DIO) mice from obesity‐induced morphological changes, such as (a, b) glomerular enlargement, (a, c) increased Bowman\'s space area, and (a, d) mesangial expansion. Moreover, MRI‐1867 treatment improved kidney function, indicated by reduced urinary (e) albumin and (f) creatinine levels, as well as (g) the albumin‐to‐creatinine ratio (ACR). (h) Reduced kidney‐to‐body weight ratio, (i) elevated blood urea nitrogen (BUN), and (j) urinary secretion levels of kidney injury marker 1 (KIM‐1), and (k) tissue inhibitor of metalloproteinase 1 (TIMP‐1) were normalized in MRI‐1867‐treated DIO mice. (l) A tendency towards reduction in creatinine clearance (CCr) was also observed in DIO mice treated with MRI‐1867. Scale bar, 20 μm. Data represent the mean ± SEM from 8 to 14 mice per group. ^\*^ *P* \< .05, significantly different from animals on STD; ^\#^ *P* \< .05, significantly different from animals on the same diet; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g003){#bph14849-fig-0003}

As MRI‐1867 inhibits both CB~1~ receptors and iNOS , we further evaluated its renal efficacy concomitantly with the orally bioavailable peripherally restricted CB~1~ receptor inverse agonist, JD5037 (3 mg·kg^−1^), and the orally bioavailable iNOS antagonist, 1400W (10 mg·kg^−1^). A parallel obese group was pair fed to the HFD‐treated group with MRI‐1867 in order to determine whether the positive renal effects of MRI‐1867 could be solely due to its effect on weight and energy homeostasis (Figure [2](#bph14849-fig-0002){ref-type="fig"}). Metabolically, both MRI‐1867 and JD5037 resulted in reduced body weight and food intake, although the latter was found to be even more effective in reducing weight (Figure [4](#bph14849-fig-0004){ref-type="fig"}a--d). Morphologically, both MRI‐1867 and JD5037 significantly reduced the HFD‐induced enlargement of glomerular and Bowman\'s space areas as well as reduced mesangial expansion (Figure [4](#bph14849-fig-0004){ref-type="fig"}e--h), and both were able to reduce circulating BUN and increase the kidney‐to‐body weight ratio (Figure [5](#bph14849-fig-0005){ref-type="fig"}a,b). However, only MRI‐1867 improved the HFD‐induced kidney dysfunction (Figure [5](#bph14849-fig-0005){ref-type="fig"}c--g). Interestingly, neither the iNOS inhibition nor pair feeding resulted in any metabolic or renal improvements (Figures [4](#bph14849-fig-0004){ref-type="fig"} and [5](#bph14849-fig-0005){ref-type="fig"}). Taken together, these findings support the pivotal roles of CB~1~ receptors and iNOS in mediating obesity‐induced renal injury and dysfunction as well as metabolic homeostasis.

![MRI‐1867 and peripheral CB~1~ receptor blockade effectively restore metabolic and kidney morphological changes in diet‐induced obese (DIO) mice in comparison with inducible NOS inhibition or pair feeding. Six‐week‐old male C57Bl/6J mice were fed with high‐fat diet (HFD) for 18 weeks and then treated chronically by oral gavage with either vehicle (Veh; 1% Tween 80, 4% DMSO, and 95% saline), MRI‐1867 (3 mg·kg^−1^), peripherally restricted CB~1~ receptor antagonist, JD5037 (3 mg·kg^−1^), and inducible NOS inhibitor, 1400W (10 mg·kg^−1^). A parallel group of mice, which was pair fed similarly to the MRI‐1867 group, was treated with Veh. Treatment was given for 28 consecutive days. MRI‐1867 and JD5037 reduced (a) body weight (BW) and (b) food intake. Both drugs reduced (c) body fat mass and increased (d) lean mass. Histologically, MRI‐1867 and JD5037 reduced (e, h) HFD‐induced glomerular enlargement, increased (f, h) Bowman\'s space area, and (g, h) mesangial expansion. Scale bar, 20 μm. Data represent the mean ± SEM from 7 to 14 mice per group. ^\*^ *P* \< .05, significantly different from diet‐induced obese animals treated with Veh; ^\#^ *P* \< .05, significantly different from diet‐induced obese mice treated with MRI‐1867; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g004){#bph14849-fig-0004}

![A greater efficacy of MRI‐1867 in restoring kidney function in diet‐induced obese mice in comparison with peripheral CB~1~ receptor blockade, inducible NOS inhibition, or pair feeding. MRI‐1867 or JD5037 treatment reduced (a) BUN levels and (b) the kidney‐to‐body weight ratio. Only MRI‐1867 was effective in reducing urinary (c) albumin, (d) creatinine, and (e) the albumin‐to‐creatinine (ACR) ratio, as well as the urinary secretion levels of (f) kidney injury marker 1 (KIM‐1) and (g) tissue inhibitor of metalloproteinase 1 (TIMP‐1). Data represent the mean ± SEM from 7 to 14 mice per group. ^\*^ *P* \< .05, significantly different from diet‐induced obese animals treated with Veh; ^\#^ *P* \< .05, significantly different from diet‐induced obese mice treated with MRI‐1867; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g005){#bph14849-fig-0005}

3.4. Dual blockade of CB~1~ receptors and iNOS decreases kidney inflammation and fibrosis in diet‐induced obese mice {#bph14849-sec-0031}
--------------------------------------------------------------------------------------------------------------------

Previous work by Cinar and colleagues emphasized the anti‐fibrogenic role of MRI‐1867, in both the liver (Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}) and the lungs (Cinar et al., [2017](#bph14849-bib-0015){ref-type="ref"}). Therefore, we also investigated its anti‐fibrogenic and anti‐inflammatory roles in the kidney. As shown in Figure [6](#bph14849-fig-0006){ref-type="fig"}, Veh‐treated DIO mice displayed up‐regulated mRNA and protein expression levels of collagen‐1 (Figure [6](#bph14849-fig-0006){ref-type="fig"}a--c), the chemokine CCL2 (Figure [6](#bph14849-fig-0006){ref-type="fig"}a,b,d), iNOS (Figure [6](#bph14849-fig-0006){ref-type="fig"}a,b,e), and TIMP‐1 (Figure [6](#bph14849-fig-0006){ref-type="fig"}a,b,f). Except for *Nos2* gene expression, the mRNA and protein levels of all of these markers were completely normalized in the MRI‐1867‐treated DIO mice. Furthermore, the elevated collagen deposition, evident in Veh‐treated DIO mice, was significantly reversed by MRI‐1867 (Figure [6](#bph14849-fig-0006){ref-type="fig"}g--j), highlighting the anti‐fibrogenic role of MRI‐1867 also in the kidney. As previously reported by us, HFD increased renal CB~1~ receptors (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}), and as expected from a compound capable of blocking CB~1~ receptors, MRI‐1867 completely down‐regulated the renal expression of CB~1~ receptors (Figure [S3](#bph14849-supitem-0001){ref-type="supplementary-material"}).

![MRI‐1867 improves renal inflammation and fibrosis in diet‐induced obese mice. Mice on standard diet (STD) or high‐fat diet (HFD) for 18 weeks were treated with vehicle (Veh) or MRI‐1867 (3 mg·kg^−1^) orally for 28 days. The HFD‐induced up‐regulation in the renal mRNA and/or the protein expression levels of (a--c) collagen‐1, (a, b, d) CCL2, (a, b, e) inducible NOS (iNOS), and (a, b, f) tissue inhibitor of metalloproteinase 1 (TIMP‐1) were attenuated or normalized in the MRI‐1867‐treated DIO mice. Similarly, the elevated collagen deposition in Veh‐treated DIO mice, measured by (g, h) Sirius Red staining and (i, j) Masson\'s trichrome staining, was reversed by chronic MRI‐1867 treatment. Scale bar, 20 μm. RQ, relative quantitation. Data represent the mean ± SEM from 8 to 14 mice per group. ^\*^ *P* \< .05, significantly different from animals on STD; ^\#^ *P* \< .05, significantly different from animals on the same diet; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g006){#bph14849-fig-0006}

3.5. Dual blockade of CB~1~ receptors and iNOS ameliorates oxidative stress in vivo and in vitro {#bph14849-sec-0032}
------------------------------------------------------------------------------------------------

Obesity‐induced oxidative stress is manifested by elevated levels of lipid oxidation (Marseglia et al., [2014](#bph14849-bib-0040){ref-type="ref"}) and decreased mitochondrial content and biogenesis (Jeon et al., [2012](#bph14849-bib-0026){ref-type="ref"}). We next tried to dissociate the inhibitory effects of CB~1~ receptors from iNOS in modulating mitochondrial function and oxidative stress by comparing the in vitro effects of MRI‐1867 with those of the peripherally restricted CB~1~ receptor blocker, JD5037, in the presence of a 0.5‐mM mixture of oleate and palmitate (O:P, 2:1, respectively). Importantly, both MRI‐1867 and JD5037 were effective in restoring ATP levels (Figure [7](#bph14849-fig-0007){ref-type="fig"}a) and mitochondrial DNA content (Figure [7](#bph14849-fig-0007){ref-type="fig"}b). However, under the same conditions, only MRI‐1867 resulted in reduced cellular ROS production (Figure [7](#bph14849-fig-0007){ref-type="fig"}c) and down‐regulated the O:P‐associated increase in the CB~1~ receptor‐independent fibrogenic expression markers, *PDGFa* (Figure [6](#bph14849-fig-0006){ref-type="fig"}d) and *FGF2* (Figure [7](#bph14849-fig-0007){ref-type="fig"}e).

![MRI‐1867 improves renal inflammation and fibrosis in diet‐induced obese mice. Mice on standard diet (STD) or high‐fat diet (HFD) for 18 weeks were treated with vehicle (Veh) or MRI‐1867 (3 mg·kg^−1^) orally for 28 days. The HFD‐induced up‐regulation in the renal mRNA and/or the protein expression levels of (a--c) collagen‐1, (a, b, d) CCL2, (a, b, e) inducible NOS (iNOS), and (a, b, f) tissue inhibitor of metalloproteinase 1 (TIMP‐1) were attenuated or normalized in the MRI‐1867‐treated DIO mice. Similarly, the elevated collagen deposition in Veh‐treated DIO mice, measured by (g, h) Sirius Red staining and (i, j) Masson\'s trichrome staining, was reversed by chronic MRI‐1867 treatment. Scale bar, 20 μm. RQ, relative quantitation. Data represent the mean ± SEM from 8 to 14 mice per group. ^\*^ *P* \< .05, significantly different from animals on STD; ^\#^ *P* \< .05, significantly different from animals on the same diet; one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g007){#bph14849-fig-0007}

We further tested the effect of MRI‐1867 in reducing O:P‐induced lipid oxidation, measured by protein‐bound 4‐HNE (Uchida et al., [1999](#bph14849-bib-0059){ref-type="ref"}), and oxidative stress in wild‐type and CB~1~R^−/−^ HK‐2 cells. Interestingly, the null cells were completely protected from the O:P‐induced up‐regulation of 4‐HNE expression (Figure [7](#bph14849-fig-0007){ref-type="fig"}f--i) and ROS production (Figure [7](#bph14849-fig-0007){ref-type="fig"}c) and, therefore, MRI‐1867 lost its effects. On the other hand, reduced ROS levels in wild‐type HK‐2 cells exposed to O:P were achieved by 100 μg·ml^−1^ of 1400W (Figure [7](#bph14849-fig-0007){ref-type="fig"}c). Assessing lipid oxidation and consequently tissue damage in our in vivo obese mouse model, by measuring 4‐HNE expression levels, revealed a marked up‐regulation in its expression in RPTCs of Veh‐treated DIO mice (Figure [7](#bph14849-fig-0007){ref-type="fig"}j,k), an effect that was completely normalized by chronic MRI‐1867 treatment. Taken together, these findings emphasize the obligatory role of CB~1~ receptors in inducing oxidative stress under obese conditions and also the unique role of MRI‐1867 in inhibiting iNOS and reducing oxidative stress in the kidney independently of inhibiting CB~1~ receptors.

3.6. Dual blockade of CB~1~ receptors and iNOS ameliorates the obesity‐induced down‐regulation of adiponectin signalling in RPTCs {#bph14849-sec-0033}
---------------------------------------------------------------------------------------------------------------------------------

Similarly to adipocytes, RPTCs are known to express adiponectin and its receptors, Adipo1 and Adipo2, (Martinez Cantarin, Keith, Waldman, & Falkner, [2014](#bph14849-bib-0041){ref-type="ref"}; Perri et al., [2013](#bph14849-bib-0048){ref-type="ref"}). As activation or blockade of CB~1~ receptors and iNOS ameliorated adiponectin expression and synthesis in adipocytes (Bensaid et al., [2003](#bph14849-bib-0006){ref-type="ref"}; Dallaire et al., [2008](#bph14849-bib-0019){ref-type="ref"}; Jeon et al., [2012](#bph14849-bib-0026){ref-type="ref"}), we sought to determine the in vivo and in vitro effect of MRI‐1867 on adiponectin signalling in RPTCs. Importantly, chronic treatment with MRI‐1867 restored the HFD‐induced reduction in renal mRNA expression of adiponectin and the Adipo2 receptor, (Figure [8](#bph14849-fig-0008){ref-type="fig"}a--c). In vitro, exposing RPTCs to O:P resulted in a similar reduction in the mRNA and protein expression levels of adiponectin (Figure [8](#bph14849-fig-0008){ref-type="fig"}d--f) as well as Adipo1 receptors (Figure [8](#bph14849-fig-0008){ref-type="fig"}g) and AdipoR2 (Figure [8](#bph14849-fig-0008){ref-type="fig"}h). Pretreatment with MRI‐1867 (100 ng·ml^−1^) completely restored these levels, suggesting that modulating adiponectin signalling by dual inhibition of CB~1~ receptors and iNOS could contribute to protecting the kidney during obesity.

![MRI‐1867 reverses the fatty acid‐induced reduction in adiponectin signalling. Mice on standard diet (STD) or high‐fat diet (HFD) for 18 weeks were treated with vehicle (Veh) or MRI‐1867 (3 mg·kg^−1^) orally for 28 days. (a--c) MRI‐1867 restored the HFD‐induced reduction in the mRNA renal expression of adiponectin, and Adipo2 but not Adipo1 receptors. Similarly, exposing HK‐2 cells to O:P (0.5 mM, 2:1, respectively) resulted in reduced (d--f) mRNA and protein expression of adiponectin as well as reduced mRNA levels of (g) Adipo1 and (h) Adipo2 receptors. Pretreatment of the cells with MRI‐1867 (100 ng·ml^−1^) completely normalized these changes. (i) A proposed mechanism for the dual blockade of CB~1~ receptors and inducible NOS by MRI‐1867 in reversing obesity‐induced chronic kidney disease (CKD) is shown. RQ, relative quantitation. In vivo data represent the mean ± SEM from 8 to 14 mice per group. ^\*^ *P* \< .05, significantly different from animals on STD; ^\#^ *P* \< .05, significantly different from animals on the same diet. In vitro data represent the mean ± SEM from five independent experiments. ^\*^ *P* \< .05, significantly different from Veh‐treated cells under normal conditions; ^\#^ *P* \< .05, significantly different from Veh‐treated cells under O:P conditions. Data were analysed by one‐way ANOVA, followed by a Bonferroni post hoc test](BPH-177-110-g008){#bph14849-fig-0008}

4. DISCUSSION {#bph14849-sec-0034}
=============

Obesity is perceived as both an initiator and accelerator of CKD (Othman, Kawar, & El Nahas, [2009](#bph14849-bib-0046){ref-type="ref"}). Interventions to prevent the development and/or progression of CKD to end‐stage renal disease have great potential to save lives as well as decrease health care‐associated costs, specifically with the increased prevalence of obesity and its co‐morbidities (Zandi‐Nejad & Brenner, [2005](#bph14849-bib-0063){ref-type="ref"}). Nonetheless, existing data suggest that the incidence of CKD differs significantly across different global regions, which have different prevalence of obesity, indicating that obesity is an important risk factor for CKD (Chalmers, Kaskel, & Bamgbola, [2006](#bph14849-bib-0010){ref-type="ref"}; Hallan et al., [2006](#bph14849-bib-0022){ref-type="ref"}). Consequently, the search for novel therapeutic targets/agents against obesity‐induced CKD has a crucial significance.

Obesity may cause deleterious effects on the kidney via inducing two main molecular signalling pathways. The first modulator, which was identified by us as a crucial player in renal lipotoxicity, is the CB~1~ receptor (Drori et al., [2019](#bph14849-bib-0021){ref-type="ref"}; Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}). Its overactivation in the kidney during obesity may lead to chronic inflammatory responses and alter the normal functioning parenchyma to exhibit more fibrogenic characteristics. These alternations impair RPTC function and, consequently, may lead to kidney dysfunction. Interestingly, this cascade of events is attributed to a halted beta‐oxidation signalling pathway governed by the LKB1/AMPK/ACC signalling pathway (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}). Moreover, activating CB~1~ receptors in RPTCs results in a parallel signalling pathway that involves recruiting the canonical fission protein, dynamin‐related protein 1, to the mitochondria to induce mitochondrial fragmentation, reduced oxygen consumption and ATP production, elevated ROS and cellular lactate levels, and a decline in mitochondrial biogenesis (Drori et al., [2019](#bph14849-bib-0021){ref-type="ref"}), contributing to renal tubular injury associated with lipotoxicity.

The second obesity‐related regulator that may affect the kidney is the iNOS signalling pathway, which is well known to promote renal dysfunction and fibrosis (Correia‐Costa et al., [2016](#bph14849-bib-0017){ref-type="ref"}) via producing the free radical NO by iNOS (Ruggiero, Ehrenshaft, Cleland, & Stadler, [2011](#bph14849-bib-0049){ref-type="ref"}). In fact, obesity provokes elevated oxidative stress by up‐regulating beta‐oxidation (Marseglia et al., [2014](#bph14849-bib-0040){ref-type="ref"}) and decreasing mitochondrial content (Jeon et al., [2012](#bph14849-bib-0026){ref-type="ref"}). Moreover, this oxidative stress is mainly derived from the production of NO by iNOS, which makes this enzyme to be considered as a fundamental perpetrator of autotoxicity (Bogdan, [1998](#bph14849-bib-0008){ref-type="ref"}).

An up‐regulation in the expression of both regulators in the kidney under diabetic conditions was reported previously (Barutta et al., [2010](#bph14849-bib-0004){ref-type="ref"}; Barutta et al., [2014](#bph14849-bib-0005){ref-type="ref"}; Chang et al., [2004](#bph14849-bib-0011){ref-type="ref"}; Cosenzi et al., [2002](#bph14849-bib-0018){ref-type="ref"}; Jenkin, McAinch, Zhang, Kelly, & Hryciw, [2015](#bph14849-bib-0025){ref-type="ref"}; Jourdan et al., [2014](#bph14849-bib-0027){ref-type="ref"}; Lim et al., [2011](#bph14849-bib-0035){ref-type="ref"}; Lim & Park, [2012](#bph14849-bib-0036){ref-type="ref"}; Nam et al., [2012](#bph14849-bib-0043){ref-type="ref"}; Slyvka et al., [2016](#bph14849-bib-0052){ref-type="ref"}; Veelken et al., [2000](#bph14849-bib-0061){ref-type="ref"}), and our current findings support these observations. However, we report here, for the first time, a strong up‐regulation of both CB~1~ receptors and iNOS in kidney samples from patients with FSGS and ORG, suggesting their pathogenic role in these CKDs. These findings in ORG patients are supported by our recent study demonstrating increased eCB "tone" in DIO mice (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}) and by the study by Kang and colleagues (Kang et al., [2015](#bph14849-bib-0029){ref-type="ref"}) indicating that expression of two genes involved in anandamide degradation (<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400> and <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1402>) are significantly reduced in renal samples collected from CKD patients, whereas <https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3084>, a key enzyme implicated in the biosynthesis of anandamide (Liu et al., [2006](#bph14849-bib-0037){ref-type="ref"}), is increased. Taken together, these changes could result in a marked CKD‐associated increase in eCB "tone" in humans as well.

Orally available peripherally restricted CB~1~ receptor antagonists , which are potentially able to ameliorate the deleterious effects of obesity, via the first signalling mechanism previously mentioned, have been preclinically tested (Tam et al., [2010](#bph14849-bib-0057){ref-type="ref"}; Tam et al., [2012](#bph14849-bib-0054){ref-type="ref"}) and have been further developed into the clinic (Chorvat, [2013](#bph14849-bib-0012){ref-type="ref"}). However, most iNOS inhibitors, targeting the second signalling mechanism, lack oral bioavailability. Therefore, obesity‐induced kidney fibrosis, oxidative stress, and dysfunction currently have no effective antifibrotic therapy approved for clinical use. By using a novel, orally bioavailable, dual‐targeted drug, MRI‐1867, which can simultaneously inhibit CB~1~ receptors and iNOS in peripheral organs (Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}), we demonstrated here, for the first time, its beneficial effect in mitigating obesity‐induced CKD. This molecule does not penetrate the brain and shows negligible occupancy of CB~1~ receptors in the CNS, as shown by PET analysis, leading to no central CB~1~ receptor‐associated side effects (Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}). In fact, this novel molecule holds promise in blocking both CB~1~ receptor and iNOS signalling in the kidney. For instance, with regard to CB~1~ receptors, its peripherally restricted inhibition creates a "positive" metabolic shift in DIO mice by decreasing body mass and food intake, as well as enhancing total energy expenditure and fat oxidation. These general metabolic effects are in accordance with a previous work published by Tam et al. ([2012](#bph14849-bib-0054){ref-type="ref"}), which investigated the efficacy of the well‐characterized, peripherally restricted CB~1~ receptor inverse agonist, JD5037, whose structure is quite similar to MRI‐1867, and which was also generated, based on the parent compound SLV‐319 (<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9234>; Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}). The positive effect of MRI‐1867 was further demonstrated here in restoring renal morphological and functional parameters in DIO mice. Whereas the morphological improvements in glomerulus size, Bowman\'s space area, and mesangial expansion, as well as the reversal of the kidney‐to‐body weight ratio and BUN, are indistinguishable from the positive effect observed in DIO mice lacking CB~1~ receptors in the RPTCs (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}) or in obese animals treated chronically with JD5037 tested here, the ability of MRI‐1867 to restore kidney function, assessed by measuring the urinary levels of albumin, creatinine, KIM‐1, and TIMP‐1, is most likely mediated via its dual action to block both CB~1~ receptors and iNOS. The renal effects of MRI‐1867 were not replicated by pair feeding, which rules out the role of a transient reduction in food intake by MRI‐1867 as their cause. This, of course, further suggests that renal CB~1~ receptors and iNOS are key modulators of nephropathy during obesity.

Notably, these improvements in DIO mice were associated with decreased inflammation and fibrosis in renal parenchyma, characterized by reduced levels of fibrogenic and proinflammatory markers such as collagen‐1, CCL2, and TIMP‐1. These modalities of MRI‐1867 are in accordance with previous studies done by Cinar and colleagues underscoring the anti‐fibrogenic role of MRI‐1867 in mitigating both liver (Cinar et al., [2016](#bph14849-bib-0016){ref-type="ref"}) and lung (Cinar et al., [2017](#bph14849-bib-0015){ref-type="ref"}) fibrosis. As MRI‐1867 induces weight loss and improves metabolic features, we could not exclude the possibility that the reversal of obesity‐induced CKD by this compound may be related to an extrinsic effect that modulates renal function indirectly and not via CB~1~ receptors and/or iNOS. Nevertheless, the additive effect of reversing obesity‐induced renal oxidative stress in DIO mice and more specifically in RPTCs can be attributed to the iNOS inhibitory modality of MRI‐1867, as its chronic administration was able to completely reduce the levels of the oxidative stress marker 4‐HNE. In addition, the up‐regulation of iNOS protein expression in the kidney of DIO mice and its reversal by MRI‐1867 strongly suggest that one should consider its involvement in obesity‐induced nephropathy. In fact, its ability to normalize the fatty acid flux‐induced up‐regulation in 4‐HNE, ROS production, and *PDGFa* and *FGF2* expression emphasizes the distinctive role of MRI‐1867 in iNOS inhibition and resolution of renal oxidative stress, independently of CB~1~ receptor inhibition. Nevertheless, we could not completely rule out the obligatory role of CB~1~ receptors in modulating renal oxidative stress as well, because knocking it out in RPTCs protected the cells from O:P‐induced lipid oxidation and oxidative stress. These results support our previous findings in mice lacking CB~1~ receptors specifically in RPTCs, which are completely protected from the deleterious effects of HFD feeding and fatty acid flux‐induced renal dysfunction, inflammation, mitochondrial damage, oxidative stress, and fibrosis (Drori et al., [2019](#bph14849-bib-0021){ref-type="ref"}; Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}).

Previous studies have shown that adiponectin has renoprotective effects in rodent experiments and that knocking it out in mice results in microalbuminuria and elevated oxidative stress (Ohashi et al., [2007](#bph14849-bib-0045){ref-type="ref"}). This led us to test the involvement of adiponectin signalling in the reversal of obesity‐induced CKD by MRI‐1867. Interestingly, activation of either CB~1~ receptors or iNOS, independently of each another, decreases adiponectin expression (Bensaid et al., [2003](#bph14849-bib-0006){ref-type="ref"}; Dallaire et al., [2008](#bph14849-bib-0019){ref-type="ref"}; Jeon et al., [2012](#bph14849-bib-0026){ref-type="ref"}) and mitigates adiponectin signalling via its receptors, Adipo1 and Adipo2 (Kabir et al., [2015](#bph14849-bib-0028){ref-type="ref"}; Tam et al., [2014](#bph14849-bib-0055){ref-type="ref"}). As reported previously (Perri et al., [2013](#bph14849-bib-0048){ref-type="ref"}), we were also able to identify adiponectin and its receptors within the kidney and more specifically in RPTCs. Interestingly, the dual blockade of CB~1~ receptors and iNOS, achieved by MRI‐1867, ameliorated obesity‐induced down‐regulation in renal adiponectin signalling both in vivo and in vitro. Others (Rutkowski et al., [2013](#bph14849-bib-0050){ref-type="ref"}; Sharma et al., [2008](#bph14849-bib-0051){ref-type="ref"}) have reported the causative relationship of adiponectin with albuminuria and oxidative stress in the kidney, most likely to be mediated via activating the energy sensor AMPK. Our previous findings, that CB~1~ receptors modulate AMPK activity to induce lipotoxicity in RPTCs and renal dysfunction (Udi et al., [2017](#bph14849-bib-0060){ref-type="ref"}), may link our two findings, suggesting that simultaneous targeting of CB~1~ receptor and iNOS signalling by MRI‐1867 could contribute to kidney protection during obesity via the induced activity of AMPK by increasing adiponectin signalling in RPTCs (Figure [8](#bph14849-fig-0008){ref-type="fig"}i).

In conclusion, this study presents the beneficial effects of a novel, orally bioavailable dual‐targeted molecule, MRI‐1867, which possesses the ability to inhibit both the CB~1~ receptor and iNOS signalling pathways, and it pharmacologically ameliorates obesity‐induced CKD. After the Food and Drug Administration recently approved testing clinically novel molecules that block CB~1~ receptors in peripheral organs for the treatment of obesity and its co‐morbidities, one should consider further emphasizing the therapeutic benefit obtained by simultaneously acting on more than one target.
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